Agile Therapeutics, Inc. Chief Medical Officer Dr. Marie Foegh Selected as One of Top 100 Healthcare Leaders by PharmaVOICE

PRINCETON, NJ--(Marketwire - August 01, 2012) -

Agile Therapeutics today announced that Dr. Marie Foegh, Chief Medical Officer and Vice President of Clinical Research and Development, has been selected as one of the top 100 leaders in the healthcare industry by PharmaVOICE, a leading publication for life-sciences executives and other healthcare-service related professionals. Dr. Foegh is recognized in the PharmaVOICE 100 for her leadership, scientific acumen and her positive contributions to the life-sciences industry.

“This special issue, now in its eighth year, has become one of the most-anticipated publications of the year, and it is our extreme pleasure to once again showcase these men and women who are providing exemplary leadership, driving change, innovating in the clinic and the market, and fostering relationships to position the industry in the best way possible to serve the ultimate stakeholders: patients,” said Taren Grom, Editor and Cofounder of PharmaVOICE.

The distinguished honorees, representing a broad cross section of industry sectors, are nominated by thousands of PharmaVOICE readers throughout the year and are selected based on how they have inspired or motivated their colleagues, peers, and even competitors; how they have influenced positive changes in their own organizations; as well as other factors, such as community and philanthropic activities.

“Dr. Marie Foegh is a truly gifted scientist, leader, and genuine advocate for improving women’s health options,” said Ms. Grom. “Her unique combination of clinical, research, and regulatory experience in both the United States and Europe provide an unmatched ability to navigate tough clinical trial design, analysis, and interpretation decisions. For her contributions to science, patients, and the development of others, PharmaVOICE is proud to name Dr. Foegh, Chief Medical Officer, VP, Clinical Research and Development, Agile Therapeutics, to the 2012 PharmaVOICE 100.”

Agile is preparing for its first commercial launch and plans to enter the contraceptive market with AG200-15, a once-weekly, low-dose contraceptive patch. Agile recently filed the NDA for AG200-15, and anticipates a response in the first quarter of 2013.

“We are extremely proud of Marie for receiving this honor,” said Al Altomari, Agile’s President and Chief Executive Officer. “Her inclusion in the PharmaVOICE 100 is not only a testament to her impressive work at Agile to bring AG200-15 to women looking for more convenient birth control options, but to her distinguished career, which has been dedicated to developing safe and effective products that give women control over their health.”

About PharmaVOICE
PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life-sciences industry. PharmaVOICE’s unique horizontal editorial approach cuts across industry silos, providing a holistic overview of the life-sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics. Editorial content sparks dialog, initiates debate, and opens the lines of communication to facilitate and improve business-to-business relationships.

PharmaVOICE’s multiple-perspective and in-depth original forums, feature articles, topics, and departments are audience-driven. PharmaVOICE provides executives with useful peer-to-peer insights on a broad range of business practices and topics to wide range of life-science sectors.

About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women’s Healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company’s lead product, AG200-15, is a once-weekly contraceptive patch that recently completed Phase III clinical trials. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.